About Impedimed
Impedimed is a publicly listed company based in Carlsbad (United States) founded in 1999. Technologies for non-invasive fluid status assessment and monitoring are developed. It operates in the Healthcare and Technology sectors. Impedimed has raised $3.44 million across 8 funding rounds from investors including Versant Ventures and Starfish Ventures. The company has 77 employees. Its chief executive, as recorded, is Rick Valencia. Its website impedimed.com draws about 11 thousand monthly visits. Impedimed offers products and services including SOZO Digital Health Platform, L-Dex Analysis, and BodyComp Analysis. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Imaging Systems. Its legal entity is IMPEDIMED INC. Its competitors include Bruker, Spectra Analysis and Ahura Scientific; 2 of its 3 listed competitors have raised funding.
Company details
Impedimed was founded in 1999 and is headquartered in Carlsbad, United States. Non-invasive medical devices are developed by the company for clinical assessment and monitoring of fluid status. These devices support surgeons, oncologists, therapists, and radiation oncologists in evaluating patients for secondary lymphoedema. Operations focus on the health technology sector, with products designed for use in oncology and related therapeutic settings.
- Annual Revenue$10.06 M (USD)14.85as on Jun 30, 2026
- Net Profit-$17.16 M (USD)-7.19as on Jun 30, 2026
- EBITDA-$12.32 M (USD)-3.11as on Jun 30, 2026
- Total Equity Funding$3.44M (USD)
in 8 rounds
- InvestorsVersant Ventures
& 1 more
- Employee Count77
Products & Services of Impedimed
Impedimed offers a comprehensive portfolio of products and services, including SOZO Digital Health Platform, L-Dex Analysis, and BodyComp Analysis.
Platform for bioimpedance spectroscopy to assess lymphedema early
Tool for monitoring lymphedema in cancer patients accurately
Analysis for segmental body composition in health assessments
Apps and channels of Impedimed
its YouTube channel ImpediMed, Inc. has 184 subscribers and 30 videos.
Videos from Impedimed
The most watched videos on Impedimed's YouTube channel, ImpediMed, Inc. (184 subscribers). Click a video to play it here.
More on ImpediMed, Inc..
Funding Insights of Impedimed
Impedimed has successfully raised a total of $3.44M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.44M
- Total Rounds 8
- First Round $3.44M
(Aug 2006)
- Investors Count 2
All 8 funding rounds of Impedimed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | Post-IPO | – | – | – | |
| Mar 2016 | $75M | Post-IPO | – | – | – |
| Mar 2014 | $10.31M | Post-IPO | – | – | – |
| Apr 2010 | $9.26M | Post-IPO | – | – | – |
| Jun 2009 | $4.04M | Post-IPO | – | – | – |
| Jul 2008 | $2.87M | Post-IPO | – | – | – |
| Jul 2008 | $1.15M | Post-IPO | – | – | – |
| Aug 2006 | $3.44M | Series A | – | Versant Ventures, Starfish Ventures | – |
2 investors in total: 2 institutional.
Investors in Impedimed
Impedimed has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Versant Ventures and Starfish Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Stage-agnostic sector-agnostic VC firm investing in Australia, New Zealand and the US | starfishvc.com | Melbourne, Australia |
Investor details for Impedimed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Impedimed
26 people are tracked at Impedimed (12 in leadership, 1 in board & advisors, 13 in team); the tracked headcount is 77.
| Name | Role | Group |
|---|---|---|
Rick Valencia | CEO & MD | Leadership |
Maulik Shah | Director Of Data Analytics | Leadership |
Shashi Tripathi | COO | Leadership |
Liana Deloudi | Office Director/talent Acquisition | Leadership |
Christy Greene | Director, Upstream Marketing | Leadership |
Steven Chen | Chief Medical Officer | Leadership |
Katie Newsome | Clinical Program Director | Leadership |
Matthew Rendina | Director Of Sales Operations | Leadership |
Adam Brown | Senior Strategic Account Director | Leadership |
Lisa Prom | VP Of Sales | Leadership |
Julie Kuhlken | Senior Director, Downstream Marketing | Leadership |
Alan Armstrong | Senior Director Manufacturing | Leadership |
Michael V. Seiden | Director | Board & advisors |
Effrosyni Garofalaki | Scrum Master | Team |
Christos Refanidis | Devops Engineer | Team |
Jim Hamilton | Key Accounts Executive | Team |
Marios Golikidis | Software Engineering Manager | Team |
Maureen L. McBeth | Senior Medical Affairs Liaison | Team |
Kathy Jones | Clinical Specialist | Team |
Nancy Deisinger | SVP Human Resources | Team |
6 more people are available in the full profile.
Complete people profiles for Impedimed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Impedimed
Impedimed is a publicly listed company on the ASX with ticker symbol IPD in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Oct 2007
- Listed onASX: IPD
- Listed entityIMPEDIMED LIMITED
- Exchange sectorHealth technology
- ISINAU000000IPD8
- Share price0.01 AUD (+16.67% on the day) · 2026-10-14
- Market capitalisation21,974,962.00 AUD
- EPS (diluted, trailing year)-0.01 AUD
- Volume (last session)2,185,525
Financials of Impedimed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 14.6M AUD | -24.9M AUD | -17.9M AUD |
| 2025 | 12.7M AUD | -23.2M AUD | -17.4M AUD |
| 2024 | 10.3M AUD | -19.8M AUD | -21.7M AUD |
| 2023 | 11.3M AUD | -20.5M AUD | -20.4M AUD |
| 2022 | 10.6M AUD | -19.9M AUD | -18.5M AUD |
Detailed financial statements for Impedimed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Impedimed
4 dated milestones of Impedimed across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Impedimed is founded.
- Funding First funding round of $3.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Impedimed
Impedimed has 3 listed competitors in our database, 2 of them funded. They include Bruker, Spectra Analysis and Ahura Scientific.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bruker.com | 1960 | United States | 9,707 | Diversified research instrument systems are manufactured and supplied. | ||
| spectra-analysis.com | 2004 | Boston, United States | $9.25M | 6 | Infrared spectroscopic instruments are provided for molecular analysis. | |
| ahurascientific.com | 2002 | Wilmington, United States | $17M | Optical systems are developed for identifying solid and liquid chemicals. |
Detailed competitors of Impedimed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Impedimed
The website of Impedimed (impedimed.com) receives about 10.9K visits a month.
- Monthly visits10.9K
▲ 20% vs previous month
Websites whose visitors overlap most with Impedimed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
lymphedivas.com | lymphedivas.com | 100% | #2,284,239 | – | |
funmedidaho.com | funmedidaho.com | 96% | #2,326,578 | – | |
mikki630-ivil.tripod.com | mikki630-ivil.tripod.com | 79% | – | ||
stepup-speakout.org | stepup-speakout.org | 78% | #6,483,085 | – | |
| lymphnet.org | 77% | 10.3K | #2,359,190 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Impedimed
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Impedimed (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Impedimed
Complete news archive for Impedimed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Impedimed
Impedimed was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Impedimed is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Rick Valencia is the CEO of Impedimed, as recorded in our data.
Impedimed is a funded company, having raised a total of $3.44M across 8 funding rounds to date. The company's 1st funding round was a Series A of $3.44M, raised on Aug 2006.
Impedimed has 77 employees.
Annual revenue of Impedimed is $10.06M as on Jun 30, 2026.
Impedimed was founded in 1999 and is headquartered in Carlsbad, United States. Non-invasive medical devices are developed by the company for clinical assessment and monitoring of fluid status. These devices support surgeons, oncologists, therapists, and radiation oncologists in evaluating patients for secondary lymphoedema. Operations focus on the health technology sector, with products designed for use in oncology and related therapeutic settings.
Impedimed's top competitors include Bruker, Spectra Analysis and Ahura Scientific.
Impedimed offers SOZO Digital Health Platform, L-Dex Analysis, and BodyComp Analysis.
Yes, Impedimed is publicly traded on ASX under the ticker symbol IPD.
Impedimed has 2 investors. Key investors include Versant Ventures, and Starfish Ventures.
Impedimed operates through Impedimed Inc.